SEC Form 4Coverage since Jul 21, 2026
$ACRV insider trading
Over the last 12 months, Acrivon Therapeutics insiders reported no purchases and 2 sales totaling $3K across SEC Form 4 filings.
- Bought · 12m
- — 0 events
- Sold · 12m
- $3K 2 events
- Events · 12m
- 2 Form 4 filings, grouped
- Insiders · 12m
- 2 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $ACRV · 12Mvia TradingView
Top insiders · 12m
Miller MaryChief Legal Officer1× · $1K
Levy Adam D.Chief Financial Officer1× · $2K
All insider trades
2 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 4, 2026 | Levy Adam D.Chief Financial Officer · O | ▼ Sale | 1,142 | $1.57 | $2K | -1.7% | — |
| Jul 21, 2026 | Miller MaryChief Legal Officer · O | ▼ Sale | 573 | $1.76 | $1K | -0.7% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ACRV feed.